AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, TWO-STAGE, PHASE 2 STUDY OF S-1 IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER To evaluate the antitumor acitivity, as assessed by objective tumor response (overall response rate [ORR] of single agent S-1 in chemotherapy-naive patients with locally advanced or metastatic pancrea...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAFENIB AS FIRST LINE THERAPY To investigate Overall Survival

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label, multicenter, randomized, phase 3 study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease To compare the Overall Survival (OS) of S-1/cisplatin therapy (experimental arm) to 5-FU/cisplatin therapy (control arm) in patients with advanced gastric cancer.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to compare TAS-102 versus TOPOTECAN OR AMRUBICIN treatment in patients requiring treatment for Small Cell Lung Cancer. Studio per confrontare il trattamento con TAS-102 rispetto a quello con topotecan o amrubicina in pazienti che richiedono un trattamento per il tumore polmonare a piccole cellule To evaluate Progression-free survival (PFS) for TAS-102 (experimental arm) and Investigator's choice of IV topotecan(control arm) in patients requiring second-line chemotherapy for SCLC refractory ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune